Cantargia presents novel preclinical data on antibody CAN04 at PEGS Europe conference
Cantargia AB today announce that new preclinical data on the antibody CAN04 is presented at the 11th annual PEGS (Protein & Antibody Engineering Summit) Europe conference, Nov 18-22 in Lisbon, Portugal. CAN04 is in clinical development for cancer and is designed to enhance immune-mediated tumor cell killing. The new results show that similar design applied to CAN04 surrogate antibodies enhance antitumor effects in experimental cancer models and further support for the strategy chosen.Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP).